Patients & Caregivers
Terminal Cancer Patient Arrested for Planning to Kill 3 Doctors
The note he left behind at his house read, "If today I do not kill them, their sins will continue."
FDA Approves Gleolan for Glioma Surgery
The FDA has approved Gleolan (aminolevulinic acid hydrochloride, ALA HCl) for use to visualize malignant tissue during glioma surgery.
Lancet Publishes Randomized Phase 3 Data for Adcetris in CTCL Patients
Takeda Pharmaceutical and Seattle Genetics Inc. announced that data from a Phase 3 clinical trial evaluating Adcetris in CTCL patients were published in Lancet.
Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine
At the ASCO Meeting, Serge Verstovsek, MD of the MD Anderson Cancer Center discussed the combination of ruxolitinib and azacytidine in myelofibrosis treatment.
Overall Survival Improved in AML Patients by Gilteritinib
New data concludes that molecular responses to gilteritinib directly correlated with clinical response and improved overall survival (OS) in patients with FLT3 mutation-positive (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML).
Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia
At the 2017 ASCO Annual Meeting, Rare Disease Report sat with Daniel DeAngelo, MD, PhD of the Dana Farber Cancer Institute to discuss acute myeloid leukemia.
Serge Verstovsek, MD Discusses Myelofibrosis and Thrombocytosis
Serge Verstovsek, MD of the MD Anderson Cancer Center sat down with RDR to discuss myelofibrosis, thrombocytosis, and potential treatment options for both.
Gerhard Zugmaier, MD Discusses Acute Lymphoblastic Leukemia
Gerhard Zugmaier, MD of Amgen and the University of Marburg sat down with RDR to discuss acute lymphoblastic leukemia.
The Angiosarcoma Project Aims to Create New DTP Approach for Identifying AS
Data concludes that a new DTP approach enabled identification of an initial cohort of angiosarcoma patients willing to share blood and medical records.
ASCO: Is Blincyto Safe and Effective in Pediatric Relapsed or Refractory ALL Patients?
At ASCO, data from an open-label, expanded access study involving children with relapsed/refractory B-precursor ALL was presented.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.